1. Euphorbium compositum SN improves the innate defenses of the airway mucosal barrier network during rhinovirus infection.
- Author
-
Rajput C, Ganjian H, Muruganandam G, Weyer K, Dannenmaier J, Seilheimer B, and Sajjan U
- Subjects
- Animals, Humans, Mice, Plant Extracts pharmacology, Plant Extracts isolation & purification, Plant Extracts therapeutic use, Respiratory Mucosa drug effects, Respiratory Mucosa virology, Respiratory Mucosa metabolism, Respiratory Mucosa immunology, Cells, Cultured, Nasal Mucosa drug effects, Nasal Mucosa virology, Nasal Mucosa metabolism, Nasal Mucosa immunology, Mice, Inbred C57BL, Immunity, Innate drug effects, Rhinovirus drug effects, Rhinovirus physiology, Picornaviridae Infections drug therapy, Picornaviridae Infections immunology, Picornaviridae Infections metabolism, Picornaviridae Infections virology
- Abstract
Background: Rhinoviruses (RV) are the major cause of common colds in healthy individuals and are associated with acute exacerbations in patients with chronic lung diseases. Yet, no vaccines or effective treatment against RV are available. This study investigated the effect of Euphorbium compositum SN (ECSN6), a multicomponent, multitarget medication made from natural ingredients, on the mucosal barrier network during RV infection., Methods: Mucociliary-differentiated airway epithelial cell cultures were infected with RV or sham, and treated with 20% ECSN6 or placebo twice daily. Barrier integrity was assessed by measuring transepithelial resistance (TER), permeability to inulin, and expression and localization of intercellular junctions proteins (IJ). Ciliary beat frequency (CBF), expression of pro-inflammatory cytokines, antiviral interferons and mucins, and viral load were also measured. C57BL/6 mice were infected intranasally with RV or sham and treated with 40% ECSN6 or placebo twice daily. Inflammation of sinunasal mucosa, localization of E-cadherin, viral load and mucin gene expression were determined., Results: ECSN6-treated, uninfected cell cultures showed small, but significant increase in TER over placebo, which was associated with enhanced localization of E-cadherin and ZO-1 to IJ. In RV-infected cultures, treatment with ECSN6, but not placebo prevented RV-induced (1) reduction in TER, (2) dissociation of E-cadherin and ZO-1 from the IJ, (3) mucin expression, and (4) CBF attenuation. ECSN6 also decreased RV-stimulated expression of pro-inflammatory cytokines and permeability to inulin. Although ECSN6 significantly increased the expression of some antiviral type I and type III interferons, it did not alter viral load. In vivo, ECSN6 reduced RV-A1-induced moderate inflammation of nasal mucosa, beneficially affected RV-A1-induced cytokine responses and Muc5ac mRNA expression and prevented RV-caused dissociation of E-cadherin from the IJ of nasal mucosa without an effect on viral clearance., Conclusions: ECSN6 prevents RV-induced airway mucosal barrier dysfunction and improves the immunological and mucociliary barrier function. ECSN6 may maintain integrity of barrier function by promoting localization of tight and adherence junction proteins to the IJ. This in turn may lead to the observed decrease in RV-induced pro-inflammatory responses in vitro. By improving the innate defenses of the airway mucosal barrier network, ECSN6 may alleviate respiratory symptoms caused by RV infections., Competing Interests: Declarations Ethics approval and consent to participate The collection of trachea and nasal brushings and use of airway basal cells was approved by Institutional Review Board, Temple University, Philadelphia, PA (4407) and University of Michigan Ann Arbor, MI (HUM00052806). The donors had written consents to use their lungs for research if the lungs were rejected for transplantation. All the experiments with animals were approved by Institutional Animal Care and User Committee, Temple University (Protocol # 4904). Consent for publication The donors provided written consent to publish the results if the donated lungs are used in research. All authors consented to publish the results. Competing interests KW, JD and BS were employed by Heel GmbH. The funders were involved in the design of the study, in the writing of the manuscript, and in the decision to publish the results, but did not have any influence on the outcome of the study., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF